individual patient TCR-transduced PBL / National Cancer Institute - Bethesda - LARVOL DELTA

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (clinicaltrials.gov) - P2 | N=285 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2028 ➔ Mar 2029 | Trial primary completion date: Mar 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Estrogen Receptor Positive Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (clinicaltrials.gov) - P1 | N=86 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P1 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology